Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article describes the unusual anti-angiogenic effects of combined hormonal blockade but reports no new research findings.

This review concludes that the global literature supports the efficacy and safety of lipidosterolic extract of Serenoa repens in treating lower urinary tract symptoms, comparable to alpha-blockers and 5α-reductase inhibitors.

This study will explore whether combination therapy with either dutasteride or finasteride and an α1 blocker is more effective than monotherapy for treating BPH, but it reports no new results.

This narrative review discusses adverse effects associated with 5-ARI treatments for male-pattern baldness and benign prostate hyperplasia, including sexual health, neurological, endocrine, metabolic, and cardiovascular impacts, and emphasizes careful prescription assessment.

This study found that compounds 21–23 and 25 exhibited strong 5α-reductase II inhibition in vitro and significantly reduced rat prostate weight, performing comparably to finasteride.

This review discusses testosterone replacement therapy, highlighting that most studies report no increased myocardial infarction risk when the therapy is properly administered with controlled hormone levels; it calls for careful consideration despite insurance coverage challenges.

This abstract details known indications, categories, and potential reactions for various drugs, including anorexiants, estrogens, NSAID analgesics, cardiac glycosides, and migraine preventives, without reporting new clinical results.

This study found that D'orenone blocks root hair growth by increasing PIN2 protein abundance, leading to reduced auxin concentration, but external auxin can reverse these effects.

This report describes a case where a food supplement containing Serenoa repens extract was associated with hot flashes and menarche in a 10-year-old girl being treated for hirsutism.

This case study found that in a male-to-female transgender individual, long-term cyproterone use led to decreased bone mass, which improved with additional oestradiol treatment, highlighting the anabolic role of oestrogens on bone health.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

In this study, low-dose oral minoxidil was found to have a favorable safety profile for treating alopecia, with mostly mild side effects, in both general and hypertensive populations.

This case report describes a postmenopausal woman who experienced facial erythema, acne, and hirsutism due to excess androgen and estrogen levels.

This study reported that while both sorafenib and lenvatinib may require dose modifications due to adverse events in treating advanced or metastatic thyroid cancers, key differences in side effect profiles were observed.

This abstract reports funding sources for ongoing research and does not present any study results.

This report advances the hypothesis that finasteride and dutasteride inhibit 5α-reductase activities, potentially altering steroid metabolism and increasing the risk of insulin resistance, diabetes, and vascular disease.

This study suggests that certain Dibenzo derivatives may be promising candidates for prostate cancer treatment due to their potential interactions with the androgen receptor and 5α-reductase enzyme.

5-ARI therapy may help prevent prostate cancer progression.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

In this study, finasteride increased cardiac damage but reduced mutagenic effects in male rats treated with anabolic steroid ND, suggesting variable organ-specific responses to metabolic inhibition.

This study reviewed recent scientific evidence on the neuroendocrine and metabolic impacts of chronic use of 5-alpha reductase inhibitors, detailing its association with sexual dysfunction, mood disorders, insulin resistance, and other metabolic disorders, suggesting persistent biopsycho-social risks beyond transient side effects in users.

In this study, bicalutamide showed promise in managing female pattern hair loss and reducing minoxidil-induced hypertrichosis, though further research is necessary to refine its use and establish its role in treatment.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

This study found that A-ring reduced derivatives of norethisterone and levonorgestrel exhibit estrogen-like potency in rat osteoblasts, suggesting a mechanism for 19-norprogestins' bone restoration effects in postmenopausal women.

This review discusses finasteride's use in manipulating neuroactive steroid levels and its potential effects on behavior, reporting preclinical evidence and clinical observations but providing no new experimental results.

This study found that Finasteride significantly reduced the proliferation of acute myeloid leukemia cell lines by inhibiting androgen receptor activity.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.